AI gene editing tools have power to modify human DNA, say researchers | BBC News

The video discusses the advancements in AI technology in healthcare, particularly focusing on its application in cancer therapy and gene editing. Companies like Electa are utilizing AI for precise tumor tracking in radiotherapy, while Profluent is using AI to develop synthetic molecules for gene editing to target genetic disorders and potentially cure diseases at the genetic level.

In this video segment, the focus is on the advancements in AI technology in the field of health, specifically in cancer therapy. The use of AI in radiotherapy, demonstrated by a company called Electa, showcases how AI is being used to track tumor movement in real-time using live MRI scanning. This technology allows for more precise treatment, potentially reducing waiting lists and improving patient outcomes. The efficiency and confidence provided by AI in delivering higher doses in fewer fractions are highlighted as crucial benefits, especially in countries like the UK where healthcare demands are high.

The discussion then shifts to the challenges of implementing AI in healthcare, with a particular focus on the NHS in the UK. The former NHS director of AI Innovation, Joseph Connor, points out the difficulties faced in adopting new AI technologies due to lack of resources, awareness, and regulatory hurdles. The initial investment in the NHS AI lab was significant, but reports indicate budget cuts, raising concerns about the ability to innovate and keep up with advancements in AI technology. The fragmented nature of the NHS and varying standards across regions pose additional challenges to widespread AI implementation.

The conversation delves into the importance of aligning standards for AI in healthcare across different regions to facilitate innovation and market access. Joseph Connor emphasizes the need for streamlined processes and evidence gathering to ensure AI technologies are safe and fit for purpose. The discussion also touches on the role of AI in gathering information and engaging with users to tailor solutions effectively. By leveraging AI to navigate regulatory requirements and develop safe and effective AI products, companies like Careful AI Limited aim to drive progress in healthcare innovation.

The video then introduces a San Francisco-based company, Profluent, that is using AI to develop synthetic molecules for gene editing. The CEO, Ali Madani, explains how their technology allows for precise editing of DNA sequences to target genetic disorders and potentially cure diseases at the genetic level. By utilizing AI to design custom medicines based on biological blueprints, Profluent represents a significant shift towards proactive, targeted treatments rather than relying on serendipitous discoveries in nature. The use of AI in gene editing offers a revolutionary approach to healthcare, enabling tailored solutions for genetic diseases and advancing the field of precision medicine.

The segment concludes with a discussion on the groundbreaking potential of AI in redesigning problematic DNA and preventing diseases at the genetic level. By combining AI with innovative technologies like CRISPR, researchers and companies are pushing the boundaries of medical science to develop bespoke, precise treatments for genetic disorders. This shift towards proactive gene editing represents a new era in healthcare, where AI-driven solutions hold the promise of personalized, effective therapies that could revolutionize disease prevention and treatment strategies.